Epizyme Company Profile

Description

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. The company’s proprietary product platform creates small molecule inhibitors of enzymes known as histone methyltransferases (HMTs). Its lead product candidate includes tazemetostat, an inhibitor of the EZH2 HMT, which is in Phase II clinical study in adults with relapsed or refractory non-Hodgkin lymphoma; and in phase II study in adults and phase I study in children with certain genetically-defined solid tumors, as well as for the treatment of mesothelioma. The company is also developing additional programs, including a Phase I clinical trial of pinometostat, an inhibitor of the DOT1L HMT for the treatment of children with MLL-r, an acute leukemia with genetic alterations of the MLL gene. It has therapeutic collaboration agreements with Celgene Corporation, Celgene RIVOT Ltd., Celgene International Sàrl, and Glaxo Group Limited, as well as with Roche Molecular Systems, Inc. and Eisai Co. Ltd.; and collaboration agreement with the Lymphoma Study Association. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.